Ireland· IE-PA-EU/1/06/366/005-16
Tandemact
A glimepiride and pioglitazone product containing glimepiride + pioglitazone, registered in Ireland by CHEPLAPHARM Arzneimittel GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Glimepiride and pioglitazone is registered in 10 of 19 countries.
Countries holding a registration under ATC A10BD06 (glimepiride and pioglitazone), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Glimepiride and pioglitazone · ATC A10BD06
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Glimepiride + Pioglitazone
- Manufacturer
- CHEPLAPHARM Arzneimittel GmbH
- Country
- Ireland (IE)
- ATC code
- A10BD06
- ATC class
- Glimepiride and pioglitazone
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/06/366/005-16
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
1 interaction on record for glimepiride and pioglitazone.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glimepiride and pioglitazone · interactions on record
1 record
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Glimepiride and pioglitazone in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesDuetactTakeda Pharmaceuticals America, Inc.
- FinlandTandemactCheplapharm Arzneimittel GmbH
- IcelandTandemactCHEPLAPHARM Arzneimittel GmbH
- NetherlandsTandemact 30 mg/2 mg, tablettenCHEPLAPHARM Arzneimittel GmbH
- PolandTandemactCHEPLAPHARM Arzneimittel GmbH
- SwedenTandemact 30 mg/2 mg TablettCheplapharm Arzneimittel GmbH
- CzechiaTANDEMACTCHEPLAPHARM Arzneimittel GmbH, Greifswald
- SpainTANDEMACT 30 mg/2 mg COMPRIMIDOSCheplapharm Arzneimittel Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tandemact
- Liechtenstein · Tandemact
- Norway · Tandemact
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cb434458-7e33-4f36-a15a-dfd2b2dd2341 GET /v1/drugs/cb434458-7e33-4f36-a15a-dfd2b2dd2341?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A10BD06"
],
"strength": null,
"pa_number": "EU/1/06/366/005-16",
"substances": [
"Glimepiride",
"Pioglitazone"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "08/01/2007",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about glimepiride and pioglitazone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.